Proposed section structure
For this topic, a clinically appropriate structure is: Highlights; Clinical background and unmet need; Biological rationale for GLP-1 signaling in reward dysfunction; Study design and methods; Key findings; Mechanistic interpretation; Clinical implications; Limitations and generalizability; Conclusion; Funding, registration, and references.
Highlights
Adjunctive oral semaglutide, given over 16 weeks to adults with major depressive disorder (MDD) and body mass index of 25 or higher, was associated with improved effort-based decision-making compared with placebo.
The treatment effect was most apparent when rewards had higher expected value, indicating greater willingness to exert effort when the reward was worth pursuing.
Computational modeling suggested that semaglutide reduced effort discounting, meaning participants treated effort as less costly relative to potential reward. By contrast, treatment did not significantly alter sensitivity to reward probability.
These findings support the view that GLP-1 receptor agonism may influence motivational processes relevant to anhedonia and amotivation in depression, but the data remain preliminary and should not yet be interpreted as establishing an antidepressant class effect.
Clinical background and unmet need
MDD is not only a disorder of low mood; it also commonly involves disturbances in reward processing, including anhedonia, reduced anticipation of reward, and diminished willingness to expend effort for desirable outcomes. These symptoms are highly clinically relevant because they are associated with functional impairment, occupational disability, poorer psychosocial recovery, and incomplete response to standard antidepressant therapy.
Traditional antidepressant trials often focus on aggregate symptom scores, yet reward-related dysfunction may persist even when overall depression severity improves. This has driven interest in translational paradigms that measure specific behavioral components of motivation. One such paradigm is the Effort-Expenditure for Rewards Task (EEfRT), a well-studied effort-based decision-making task that quantifies willingness to work for rewards under varying levels of effort, reward magnitude, and reward probability.
At the same time, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have moved from diabetes care into obesity treatment and broader cardiometabolic prevention. Beyond their peripheral metabolic effects, GLP-1 receptors are expressed in brain regions involved in reward valuation, salience, and motivated behavior. Preclinical and emerging human data have therefore raised the possibility that GLP-1 receptor signaling may influence reward processing in ways that extend beyond appetite regulation.
The present randomized clinical trial is notable because it tests that hypothesis directly in a psychiatric population. Specifically, it examines whether semaglutide can modify a measurable behavioral dimension of reward dysfunction in patients with MDD.
Biological rationale for GLP-1 signaling in reward dysfunction
GLP-1 signaling has attracted interest in neuropsychiatry because it links metabolic state to central motivational circuits. Experimental work suggests that GLP-1 receptor activation can modulate mesolimbic pathways, including dopaminergic systems involved in valuation and effort allocation. This does not imply a simple dopamine-boosting model. Rather, GLP-1 signaling may alter how organisms weigh energetic cost against anticipated benefit.
That distinction matters in depression. Many patients with MDD do not merely report reduced pleasure; they often describe everyday actions as feeling disproportionately effortful. In behavioral economic terms, the perceived cost of effort may be inflated relative to expected reward. If a treatment reduces effort discounting, it could improve goal-directed behavior even without directly changing hedonic tone.
Semaglutide is especially interesting in this context because it is a potent GLP-1 RA with established systemic effects on appetite, body weight, glycemic control, and inflammatory-metabolic pathways that may intersect with depressive pathophysiology. Whether those mechanisms translate into clinically meaningful changes in motivational behavior has been uncertain until now.
Study design and methods
Gill and colleagues conducted a 16-week, double-blind, placebo-controlled, parallel-group randomized clinical trial at the Mood Disorders Psychopharmacology Unit, University Health Network, Toronto. Participants were recruited between March 14, 2022, and July 26, 2024, and data analysis was performed from January 7, 2025, through February 3, 2025.
The trial enrolled 72 adults with a diagnosis of MDD and a body mass index of at least 25. Participants were randomized 1:1 to adjunctive oral semaglutide or placebo in addition to treatment as usual. Thirty-five participants were assigned to semaglutide and 37 to placebo. Mean age was 38.17 years in the semaglutide group and 40.27 years in the placebo group; just over half of participants in each arm were female.
The intervention used oral semaglutide, titrated from 4 mg to 14 mg using a 4-week dose-escalation regimen, then continued adjunctively. The prespecified outcome for this secondary analysis was performance on the EEfRT. This is important: the article reports a secondary analysis of a randomized clinical trial, not a stand-alone trial designed solely around the motivation endpoint. Even so, the outcome was preregistered, which strengthens interpretability and reduces concern about purely post hoc signal fishing.
The EEfRT is designed to capture effort-based choice behavior. Participants choose between options that vary in required effort and potential reward, with the reward also weighted by probability. This allows investigators to separate willingness to expend effort from sensitivity to reward magnitude or uncertainty. The authors also used computational modeling to estimate latent decision parameters, including effort discounting and probability sensitivity.
Key findings
The central result was a significant treatment by visit by expected value interaction on EEfRT performance, with a reported chi-square value of 12.024 and P = .02. In practical terms, participants receiving semaglutide showed an increased willingness over time to exert higher physical effort when the expected value of reward was greater. This pattern suggests more adaptive cost-benefit calibration rather than a nonspecific increase in activity or indiscriminate risk taking.
The computational findings sharpen the interpretation. Semaglutide’s effect on choice behavior appeared to be driven by reduced effort discounting. Sensitivity to effort was significantly reduced with semaglutide treatment, with beta = -1.737 and P = .03. By contrast, there was no significant treatment effect on sensitivity to probability, with beta = -0.776 and P = .51.
This dissociation is clinically and mechanistically informative. It implies that semaglutide did not simply make participants more optimistic about uncertain rewards, nor did it broadly alter probability processing. Instead, the drug appears to have changed how effort costs were integrated into decision-making. Stated more clinically, semaglutide-treated participants behaved as though effort “cost less” relative to what could be gained.
That is a conceptually meaningful result in MDD, where reduced goal-directed behavior may stem from an exaggerated internal cost signal. The study therefore supports a model in which GLP-1 receptor agonism can influence motivational valuation in depression.
The abstract does not report confidence intervals for these behavioral parameters, nor does it provide full symptom-scale outcomes, remission rates, or detailed adverse event data for this secondary analysis. As a result, the findings are best interpreted as a mechanistic behavioral signal rather than direct evidence of symptomatic antidepressant efficacy.
How should clinicians interpret the effect?
The most important takeaway is not that semaglutide is now a treatment for depression. Rather, this study suggests that semaglutide may target a specific dimension of psychopathology: reward-related motivational impairment, especially the tendency to overvalue effort cost. For clinicians, that matters because motivational deficits often remain undertreated and functionally disabling.
There are several possible clinical interpretations. First, if replicated, GLP-1 RAs may eventually emerge as transdiagnostic tools for disorders characterized by effort-related motivational abnormalities, not only MDD but potentially conditions such as bipolar depression, schizophrenia-spectrum negative symptoms, and some substance-use disorders. Second, these data reinforce the idea that psychiatric therapeutics should be evaluated not only by symptom checklists but also by computationally informed behavioral phenotypes.
However, caution is essential. The trial enrolled participants with MDD and body mass index 25 or higher, so generalizability to patients with lower body weight is unknown. Because semaglutide has substantial effects on weight and appetite, it is also possible that changes in energy balance, inflammation, insulin signaling, or interoceptive state contributed indirectly to motivational changes. The study design does not fully disentangle central reward-circuit effects from broader metabolic effects.
Mechanistic interpretation and translational relevance
This study is particularly valuable because it moves beyond broad claims about mood improvement and interrogates a more precise behavioral construct. Effort discounting refers to the decline in subjective value of a reward as the amount of required effort increases. In depression, effort discounting may be pathologically steep, leading patients to disengage from even potentially meaningful opportunities. A reduction in effort discounting therefore represents a plausible mechanism by which patients might re-engage with work, exercise, socialization, or treatment tasks.
The absence of a significant probability effect is equally important. If semaglutide had increased reward pursuit by making participants less sensitive to uncertainty, one might worry about indiscriminate or maladaptive reward seeking. Instead, the pattern observed is more selective and arguably more therapeutically desirable: individuals became more willing to work when the expected value justified the effort.
From a translational standpoint, these findings fit with growing interest in metabolic psychiatry. This field examines how hormones, inflammation, mitochondrial energetics, insulin resistance, and body composition interact with brain function and psychopathology. Semaglutide, because it sits at the interface of metabolic and central signaling, is a natural candidate for this line of investigation.
Limitations and generalizability
Several limitations temper the conclusions. The sample size was modest, with 72 randomized participants, which is reasonable for a mechanistic trial but limited for definitive treatment inference. The report summarized here is a secondary analysis, even though preregistered; therefore, the broader parent-trial context remains relevant when judging robustness.
The abstract does not provide detailed depressive symptom outcomes, functional outcomes, dropout rates, adherence metrics, or safety findings specific to this analysis. In a medication class known for gastrointestinal adverse effects, tolerability and blinding integrity are important considerations. If adverse effects differed meaningfully between groups, expectancy or behavior could in theory influence task performance.
External validity is also constrained. Participants had MDD plus overweight or obesity, were treated in a university-based mood disorders program, and received semaglutide adjunctively to treatment as usual. It remains unclear whether similar effects would be seen in normal-weight patients, in primary care populations, or in semaglutide-naive individuals with different comorbidity burdens.
Finally, a behavioral task outcome, while mechanistically rich, is not the same as a patient-centered outcome. Improved EEfRT performance does not automatically translate into improved employment, social functioning, self-care, or quality of life. Future trials should test whether changes in effort discounting mediate real-world functional recovery.
Clinical implications for current practice
For now, semaglutide should not be prescribed solely to treat motivational symptoms in MDD on the basis of this single study. The data are promising, but they remain early-stage. Nonetheless, the findings may influence clinical thinking in several ways.
First, they support more nuanced assessment of reward dysfunction in depression, especially among patients who report that everyday tasks feel effortful rather than unrewarding in a purely hedonic sense. Second, they encourage clinicians to consider the metabolic context of psychiatric illness, particularly in patients with comorbid obesity or insulin resistance. Third, they highlight the value of dimensional and computational phenotyping in psychopharmacology development.
If subsequent trials confirm symptomatic and functional benefit, semaglutide or related GLP-1 RAs might eventually be studied as targeted adjuncts for patients with depression marked by prominent amotivation, metabolic dysfunction, or both. Such an approach would align with precision psychiatry rather than one-size-fits-all antidepressant prescribing.
Conclusion
This randomized clinical trial provides evidence that adjunctive oral semaglutide can alter effort-based decision-making in adults with MDD and body mass index 25 or higher. The key signal was a reduction in effort discounting, not a change in probability sensitivity, suggesting a specific shift in how effort cost is weighed against reward.
The study does not establish semaglutide as an antidepressant treatment for general use, but it does offer an important proof of concept: GLP-1 receptor agonism may modify a core behavioral process underlying motivational dysfunction in depression. That makes the trial relevant not only to psychiatrists but also to endocrinologists, translational neuroscientists, and clinicians interested in the emerging field of metabolic psychiatry.
The next steps are clear. Larger trials should determine whether these task-based effects replicate, whether they predict improvements in depressive symptoms and functioning, which patients benefit most, and how metabolic and central mechanisms interact. Until then, this study stands as a compelling mechanistic advance rather than a practice-changing therapeutic mandate.
Funding and trial registration
ClinicalTrials.gov identifier: NCT04466345.
The abstract provided does not specify funding details. Readers should consult the full JAMA Psychiatry publication for complete information on funding sources, author disclosures, and adverse event reporting.
References
1. Gill H, Badulescu S, Shah H, Brudner RM, Phan L, Di Vincenzo JD, Tabassum A, Thanarajah SE, Llach CD, Rosenblat JD, McIntyre RS, Mansur RB. Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Apr 29. PMID: 42054055.
2. Treadway MT, Buckholtz JW, Schwartzman AN, Lambert WE, Zald DH. Worth the “EEfRT”? The effort expenditure for rewards task as an objective measure of motivation and anhedonia. PLoS One. 2009;4(8):e6598.
3. Husain M, Roiser JP. Neuroscience of apathy and anhedonia: a transdiagnostic approach. Nat Rev Neurosci. 2018;19(8):470-484.
4. Anderberg RH, Richard JE, Hansson C, Nissbrandt H, Bergquist F, Skibicka KP. GLP-1 is both anxiogenic and antidepressant; divergent effects of acute and chronic GLP-1 on emotionality. Psychoneuroendocrinology. 2016;65:54-66.
5. Mansur RB, Brietzke E, McIntyre RS. Is there a “metabolic-mood syndrome”? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015;52:89-104.
6. McIntyre RS, Subramaniapillai M, Lee Y, Pan Z, Carmona NE, Shekotikhina M, Rosenblat JD, Brietzke E, Soczynska JK. Efficacy of adjunctive nutraceuticals for major depressive disorder: mechanisms and metabolic considerations in precision psychiatry. Harv Rev Psychiatry. 2021;29(1):1-20.